197 related articles for article (PubMed ID: 23313399)
1. Characterisation and clinical features of Enterobacter cloacae bloodstream infections occurring at a tertiary care university hospital in Switzerland: is cefepime adequate therapy?
Hilty M; Sendi P; Seiffert SN; Droz S; Perreten V; Hujer AM; Bonomo RA; Mühlemann K; Endimiani A
Int J Antimicrob Agents; 2013 Mar; 41(3):236-49. PubMed ID: 23313399
[TBL] [Abstract][Full Text] [Related]
2. Cefepime Therapy for Monomicrobial Enterobacter cloacae Bacteremia: Unfavorable Outcomes in Patients Infected by Cefepime-Susceptible Dose-Dependent Isolates.
Lee NY; Lee CC; Li CW; Li MC; Chen PL; Chang CM; Ko WC
Antimicrob Agents Chemother; 2015 Dec; 59(12):7558-63. PubMed ID: 26416853
[TBL] [Abstract][Full Text] [Related]
3. Risk factors and outcome of extended-spectrum β-lactamase-producing Enterobacter cloacae bloodstream infections.
Qureshi ZA; Paterson DL; Pakstis DL; Adams-Haduch JM; Sandkovsky G; Sordillo E; Polsky B; Peleg AY; Bhussar MK; Doi Y
Int J Antimicrob Agents; 2011 Jan; 37(1):26-32. PubMed ID: 21075605
[TBL] [Abstract][Full Text] [Related]
4. Emerging resistance to ceftriaxone treatment owing to different ampD mutations in Enterobacter roggenkampii.
Xie L; Xu R; Zhu D; Sun J
Infect Genet Evol; 2022 Aug; 102():105301. PubMed ID: 35568334
[TBL] [Abstract][Full Text] [Related]
5. Efficacies of imipenem, meropenem, cefepime, and ceftazidime in rats with experimental pneumonia due to a carbapenem-hydrolyzing beta-lactamase-producing strain of Enterobacter cloacae.
Mimoz O; Leotard S; Jacolot A; Padoin C; Louchahi K; Petitjean O; Nordmann P
Antimicrob Agents Chemother; 2000 Apr; 44(4):885-90. PubMed ID: 10722486
[TBL] [Abstract][Full Text] [Related]
6. Assessing antimicrobial stewardship initiatives: Clinical evaluation of cefepime or piperacillin/tazobactam in patients with bloodstream infections secondary to AmpC-producing organisms.
McKamey L; Venugopalan V; Cherabuddi K; Borgert S; Voils S; Shah K; Klinker KP
Int J Antimicrob Agents; 2018 Nov; 52(5):719-723. PubMed ID: 30125680
[TBL] [Abstract][Full Text] [Related]
7. Antibiotic resistance in Enterobacter cloacae strains with derepressed/partly derepressed/inducible AmpC and extendedspectrum beta-lactamases in Zenica-Doboj Canton, Bosnia and Herzegovina.
Uzunović S; Ibrahimagić A; Bedenić B
Med Glas (Zenica); 2018 Feb; 15(1):37-45. PubMed ID: 29214986
[TBL] [Abstract][Full Text] [Related]
8. Extension of resistance to cefepime and cefpirome associated to a six amino acid deletion in the H-10 helix of the cephalosporinase of an Enterobacter cloacae clinical isolate.
Barnaud G; Labia R; Raskine L; Sanson-Le Pors MJ; Philippon A; Arlet G
FEMS Microbiol Lett; 2001 Feb; 195(2):185-90. PubMed ID: 11179650
[TBL] [Abstract][Full Text] [Related]
9. SHV-type extended-spectrum beta-lactamase production is associated with Reduced cefepime susceptibility in Enterobacter cloacae.
Szabó D; Bonomo RA; Silveira F; Pasculle AW; Baxter C; Linden PK; Hujer AM; Hujer KM; Deeley K; Paterson DL
J Clin Microbiol; 2005 Oct; 43(10):5058-64. PubMed ID: 16207962
[TBL] [Abstract][Full Text] [Related]
10. Susceptibility patterns to extended-spectrum cephalosporins among Enterobacteriaceae harbouring extended-spectrum β-lactamases using the updated Clinical and Laboratory Standards Institute interpretive criteria.
Kristo I; Pitiriga V; Poulou A; Zarkotou O; Kimouli M; Pournaras S; Tsakris A
Int J Antimicrob Agents; 2013 Apr; 41(4):383-7. PubMed ID: 23375981
[TBL] [Abstract][Full Text] [Related]
11. What does the susceptible-dose dependent interpretive category for cefepime in ESBL-producing bacteria?
Menegucci TC; Bastos MS; Viana GF; Moreira RRB; Garcia LB; Cardoso CL; Tognim MCB
J Chemother; 2017 Jun; 29(3):189-194. PubMed ID: 27077929
[TBL] [Abstract][Full Text] [Related]
12. Cefepime, not Piperacillin/Tazobactam use, for empirical treatment of bloodstream infections caused by Enterobacter spp.: Results from a population pharmacokinetic/pharmacodynamic analysis.
Shi Q; Huang C; Chen W; Wu S; Ji J; Ying C; Wu H; Xiao Y
Eur J Pharm Sci; 2023 Jan; 180():106334. PubMed ID: 36402309
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of extended-spectrum beta-lactamases in Enterobacter cloacae in Taiwan and comparison of 3 phenotypic confirmatory methods for detecting extended-spectrum beta-lactamase production.
Yang JL; Wang JT; Lauderdale TL; Chang SC
J Microbiol Immunol Infect; 2009 Aug; 42(4):310-6. PubMed ID: 19949754
[TBL] [Abstract][Full Text] [Related]
14. Cefepime vs other antibacterial agents for the treatment of Enterobacter species bacteremia.
Siedner MJ; Galar A; Guzmán-Suarez BB; Kubiak DW; Baghdady N; Ferraro MJ; Hooper DC; O'Brien TF; Marty FM
Clin Infect Dis; 2014 Jun; 58(11):1554-63. PubMed ID: 24647022
[TBL] [Abstract][Full Text] [Related]
15. Extended double disc synergy testing reveals a low prevalence of extended-spectrum beta-lactamases in Enterobacter spp. in Vienna, Austria.
Apfalter P; Assadian O; Daxböck F; Hirschl AM; Rotter ML; Makristathis A
J Antimicrob Chemother; 2007 May; 59(5):854-9. PubMed ID: 17347178
[TBL] [Abstract][Full Text] [Related]
16. Is Carbapenem Therapy Necessary for the Treatment of Non-CTX-M Extended-Spectrum β-Lactamase-Producing Enterobacterales Bloodstream Infections?
Hareza DA; Cosgrove SE; Simner PJ; Harris AD; Bergman Y; Conzemius R; Jacobs E; Beisken S; Tamma PD
Clin Infect Dis; 2024 May; 78(5):1103-1110. PubMed ID: 37972276
[TBL] [Abstract][Full Text] [Related]
17. Cefepime and amikacin synergy in vitro and in vivo against a ceftazidime-resistant strain of Enterobacter cloacae.
Mimoz O; Jacolot A; Padoin C; Tod M; Samii K; Petitjean O
J Antimicrob Chemother; 1998 Mar; 41(3):367-72. PubMed ID: 9578163
[TBL] [Abstract][Full Text] [Related]
18. Activity of Ceftolozane-Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae Isolates Collected from Respiratory Tract Specimens of Hospitalized Patients in the United States during 2013 to 2015.
Castanheira M; Duncan LR; Mendes RE; Sader HS; Shortridge D
Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263073
[TBL] [Abstract][Full Text] [Related]
19. Cefepime therapy for monomicrobial bacteremia caused by cefepime-susceptible extended-spectrum beta-lactamase-producing Enterobacteriaceae: MIC matters.
Lee NY; Lee CC; Huang WH; Tsui KC; Hsueh PR; Ko WC
Clin Infect Dis; 2013 Feb; 56(4):488-95. PubMed ID: 23090931
[TBL] [Abstract][Full Text] [Related]
20. Molecular and epidemiological characterization of IMP-type metallo-β-lactamase-producing Enterobacter cloacae in a Large tertiary care hospital in Japan.
Hayakawa K; Miyoshi-Akiyama T; Kirikae T; Nagamatsu M; Shimada K; Mezaki K; Sugiki Y; Kuroda E; Kubota S; Takeshita N; Kutsuna S; Tojo M; Ohmagari N
Antimicrob Agents Chemother; 2014 Jun; 58(6):3441-50. PubMed ID: 24709261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
